Titlebook: Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis; Albert V. G. Bruschke,Johan H. C. Reiber,Hein J. J Book 1996 Kluwer Ac

領(lǐng)袖氣質(zhì)

果核

Lipid-Lowering Therapy and Progression of Coronary Atherosclerosis978-94-009-0143-8Series ISSN 0166-9842

苦笑

Angiographic endpoints in progression trials, this is an avoidable problem and therefore a serious attempt at standardization should be made. This chapter reviews the criteria which have been used in trials using quantitative coronary angiography and presents a proposal for standardization.

Enzyme

The Cholesterol Lowering Atherosclerosis Study (CLAS)al to conclusively demonstrate the angiographic benefit of lipid lowering therapy, first at two and subsequently more pronounced at four years. Recently, long-term clinical follow-up has been completed.

雪上輕舟飛過

Effects of the lipid intervention in the Stanford Coronary Risk Intervention Projectge from entry to four-year follow-up angiograms in minimum lumen diameter of diseased segments in 245 subjects was analysed in relation to hypolipidaemic medication and lipid-related risk factors. Greater disease progression was associated with non-use of hypolipidaemic drugs and higher blood glucose and insulin levels.

現(xiàn)任者

謙卑

https://doi.org/10.1007/978-94-009-0143-8Bypass; Lipoprotein; atherosclerosis; coronary artery disease; coronary heart disease

處理

Hormones

Lethargic

1997, 1999b) both highlight the extent to which the decision to establish foreign subsidiaries is influenced by the need to appropriate the rents accruing from investment in firm-specific knowledge-based assets and practices. Many new theoretical models also view the creation and exploitation of kn